MindRank
's headquarters is located in Hangzhou, Zhejiang Province. Niu Zhangming is the Founder & CEO of MindRank. MindRank's latest funding round was a Series A for $20M on Jul 2023. MindRank has 1 followers on Owler. MindRank has an estimated revenue of <$1M and an estimate of less <10 employees.MindRank
's headquarters is located in Hangzhou, Zhejiang Province. Niu Zhangming is the Founder & CEO of MindRank. MindRank's latest funding round was a Series A for $20M on Jul 2023. MindRank has 1 followers on Owler. MindRank has an estimated revenue of <$1M and an estimate of less <10 employees.
Founder & CEO
Niu Zhangming
News
Sep 29, 2025
GlobalNewswire
Press Release: MindRank : MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity
Jun 25, 2025
Clinical Trials Arena
MindRank: MindRank's AI-designed oral GLP-1RA succeeds in Phase IIb trial
Mar 07, 2025
GlobalNewswire
Press Release: MindRank : Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline
Jul 24, 2023
ChinaBio Today
MindRank: MindRank Raises $20 Million in A+ Round to Support AI Drug Development Operations
Jun 15, 2023
ChinaBio Today
MindRank: MindRank Starts Trial of AI-Discovered GLP-1 Agonist for Obesity and T2DM
Jun 14, 2023
FinanzNachrichten
MindRank: MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
Dec 27, 2022
Indian Pharma Post
MindRank: MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
Jan 18, 2022
FinanzNachrichten
MindRank: MindRank AI: MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation
Aug 10, 2021
Pharmabiz
MindRank: Antengene inks pact with MindRank to develop firstinclass smallmolecule oncology drugs
Aug 09, 2021
Biospectrum Asia
MindRank: Chinese firms to advance the drug development for hard-to-drug molecular targets